PCV10 elicits Protein D IgG responses in Papua New Guinean children but has no impact on NTHi carriage in the first two years of life
Tasmina Rahman, Camilla de Gier, Tilda Orami, Elke J Seppanen, Caitlyn M Granland, Jacinta P Francis, Audrey Michael, Mition Yoannes, Karli J Corscadden, Rebecca L Ford, Kelly M Martinovich, Peter Jacoby, Anita H J van den Biggelaar, Deborah Lehmann, Peter C Richmond, William S Pomat, Ruth B Thornton, Lea-Ann S Kirkham, Tasmina Rahman, Camilla de Gier, Tilda Orami, Elke J Seppanen, Caitlyn M Granland, Jacinta P Francis, Audrey Michael, Mition Yoannes, Karli J Corscadden, Rebecca L Ford, Kelly M Martinovich, Peter Jacoby, Anita H J van den Biggelaar, Deborah Lehmann, Peter C Richmond, William S Pomat, Ruth B Thornton, Lea-Ann S Kirkham
Abstract
Background: Nasopharyngeal colonisation with nontypeable Haemophilus influenzae (NTHi) is associated with development of infections including pneumonia and otitis media. The 10-valent pneumococcal conjugate vaccine (PCV10) uses NTHi Protein D (PD) as a carrier. Papua New Guinean children have exceptionally early and dense NTHi carriage, and high rates of NTHi-associated disease. Vaccination with PCV10 could potentially reduce NTHi carriage and disease in this population by inducing a NTHi PD immune response.
Methods: Serum and nasopharyngeal swabs were collected from 101 Papua New Guinean children at 1, 4, 9, 10, 23 and 24 months of age. Children received PCV10 (n = 55) or PCV13 (not containing NTHi PD) (n = 46) at 1, 2 and 3 months of age. NTHi carriage density was measured in swabs by qPCR. Serum PD-IgG levels were measured by bead-based immunoassay.
Results: Papua New Guinean children did naturally develop PD-IgG antibodies whose levels were increased at 4 months of age with PCV10 vaccination at 1-2-3 months. Despite this, most children were colonised with NTHi by 4 months of age (~95%) regardless of being vaccinated with PCV10 or PCV13, and PCV10 had no impact on NTHi carriage density.
Conclusion: Early vaccination of infants with PCV10 elicited a robust PD antibody response but this had no impact on NTHi carriage.
Trial registration: ClinicalTrials.gov CTN NCT01619462.
Keywords: Carriage density; NTHi; Nontypeable Haemophilus influenzae; Papua New Guinea; Pneumococcal conjugate vaccine; Protein D.
Conflict of interest statement
Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: W. S. P. has received funding from Pfizer Australia to attend a conference. A. H. J. v. d. B. was previously an employee of Janssen Pharmaceuticals, Johnson and Johnson, and conducts part-time consultancy work for vaccine companies on projects not related to this study. L. A. K. has received investigator-initiated research grants, educational grants and travel support from Pfizer, GlaxoSmithKline and Merck Sharp & Dohme, and is an inventor on patents for a pneumococcal protein vaccine antigen. D. L. has received support from Pfizer Australia to attend conferences, an honorarium from Merck Vaccines to give a seminar at their offices in Pennsylvania and support from Merck Vaccines to attend a conference; and is an investigator on an investigator-initiated research grant that was funded by Pfizer Australia. P. C. R. has received nonfinancial support from Pfizer, grants from GlaxoSmithKline and Pfizer, and nonfinancial support from GlaxoSmithKline for work outside the submitted work. The Papua New Guinea Institute of Medical Research received sponsorship from Pfizer Australia to host a national Medical Symposium in 2014. All other authors declare no competing interests.
Copyright © 2021. Published by Elsevier Ltd.
Source: PubMed